Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Contezolid Acefosamil vs Linezolid in ABSSSI
NCT03747497Phase 2Completed
- Sponsor
- MicuRx Pharmaceuticals
- Start
- Nov 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of contezolid acefosamil in acute bacterial skin and skin structure infection (ABSSSI) (2 arms), sponsored by MicuRx Pharmaceuticals. Primary endpoint: Early Clinical Response. Started Nov 2018; status: completed.
02
Drugs
contezolid acefosamil
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on NCT03747497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03747497.